Russell Investments Group Ltd. Raises Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Russell Investments Group Ltd. boosted its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 187.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,953 shares of the company’s stock after buying an additional 19,543 shares during the period. Russell Investments Group Ltd.’s holdings in Arcus Biosciences were worth $446,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Wells Fargo & Company MN raised its position in shares of Arcus Biosciences by 105.9% during the 4th quarter. Wells Fargo & Company MN now owns 38,618 shares of the company’s stock valued at $575,000 after buying an additional 19,865 shares in the last quarter. ExodusPoint Capital Management LP bought a new stake in Arcus Biosciences during the fourth quarter worth about $896,000. Trexquant Investment LP lifted its holdings in shares of Arcus Biosciences by 241.5% in the 4th quarter. Trexquant Investment LP now owns 300,548 shares of the company’s stock worth $4,475,000 after acquiring an additional 212,552 shares during the last quarter. Norges Bank purchased a new position in shares of Arcus Biosciences in the fourth quarter worth $507,000. Finally, WINTON GROUP Ltd increased its stake in shares of Arcus Biosciences by 5.4% during the fourth quarter. WINTON GROUP Ltd now owns 72,310 shares of the company’s stock valued at $1,077,000 after buying an additional 3,730 shares during the period. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on RCUS. Barclays reduced their price objective on Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating for the company in a research report on Wednesday. HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. Morgan Stanley reduced their target price on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Finally, Bank of America lowered their price target on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $28.38.

Arcus Biosciences Trading Up 0.4 %

Shares of NYSE:RCUS opened at $8.12 on Thursday. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $18.98. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The stock has a market capitalization of $853.72 million, a price-to-earnings ratio of -2.58 and a beta of 1.54. The stock’s 50-day simple moving average is $8.94 and its two-hundred day simple moving average is $13.19.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.17) by $0.14. The business had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, Director Yasunori Kaneko bought 20,000 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was acquired at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the transaction, the director now owns 28,400 shares in the company, valued at $285,704. This trade represents a 238.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Terry J. Rosen bought 19,800 shares of the stock in a transaction dated Thursday, February 27th. The shares were bought at an average cost of $10.18 per share, with a total value of $201,564.00. Following the completion of the purchase, the chief executive officer now directly owns 2,554,160 shares of the company’s stock, valued at approximately $26,001,348.80. This trade represents a 0.78 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.